Andrea Zanichelli
Overview
Explore the profile of Andrea Zanichelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zuraw B, Bork K, Bouillet L, Christiansen S, Farkas H, Germenis A, et al.
Clin Rev Allergy Immunol
. 2025 Mar;
68(1):24.
PMID: 40053270
Hereditary angioedema (HAE) has been recognized for almost 150 years. The newest form of HAE, where C1 inhibitor levels are normal (HAE-nC1INH), was first described in 2000. Over the last...
2.
Baroni I, Paglione G, De Angeli G, Angolani M, Callus E, Magon A, et al.
Health Qual Life Outcomes
. 2025 Feb;
23(1):12.
PMID: 39948647
Background: Hereditary angioedema (HAE) adversely affects health-related quality of life (HRQoL). HAE often compromises the HRQoL due to the impact on functional capacity caused by edema, pain, other symptoms, and...
3.
Berra S, Parolin D, Suffritti C, Folcia A, Zanichelli A, Gusso L, et al.
Life (Basel)
. 2025 Jan;
14(12.
PMID: 39768234
Background: Although more than four years have passed since the pandemic began, SARS-CoV-2 continues to be of concern. Therefore, research into the underlying mechanisms that contribute to the development of...
4.
Costanzo G, Sambugaro G, Sartorio S, Zanichelli A, Firinu D
Expert Opin Biol Ther
. 2024 Dec;
25(1):79-91.
PMID: 39664008
Introduction: Revolutionary drugs have been developed and approved in the last 5 years for the treatment of hereditary angioedema (HAE). Increased knowledge of HAE pathophysiology has led to the development...
5.
Gidaro A, La Cava L, Donadoni M, Popescu Janu V, Cogliati C, Brucato A, et al.
Front Immunol
. 2024 Oct;
15:1472390.
PMID: 39399485
Introduction: Cardiovascular pathologies represent the first cause of death in uremic patients and are among the leading causes of mortality in patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH)....
6.
dApolito M, Santacroce R, Vazquez D, Cordisco G, Fantini C, DAndrea G, et al.
J Allergy Clin Immunol
. 2024 Jun;
154(3):698-706.
PMID: 38823490
Background: In the recent years, there was an important improvement in the understanding of the pathogenesis of hereditary angioedema (HAE). Notwithstanding, in a large portion of patients with unknown mutation...
7.
Riedl M, Farkas H, Aygoren-Pursun E, Psarros F, Soteres D, Staevska M, et al.
N Engl J Med
. 2024 May;
391(1):32-43.
PMID: 38819658
Background: Approved on-demand treatments for hereditary angioedema attacks need to be administered parenterally, a route of administration that is associated with delays in treatment or withholding of therapy. Methods: In...
8.
Reshef A, Buttgereit T, Betschel S, Caballero T, Farkas H, Grumach A, et al.
J Allergy Clin Immunol
. 2024 Apr;
154(2):398-411.e1.
PMID: 38670233
Background: Angioedema (AE) manifests with intermittent, localized, self-limiting swelling of the subcutaneous and/or submucosal tissue. AE is heterogeneous, can be hereditary or acquired, may occur only once or be recurrent,...
9.
Zanichelli A, Senter R, Merlo A, Gidaro A, Popescu Janu V, Cogliati C, et al.
J Allergy Clin Immunol Pract
. 2024 Jan;
12(4):1029-1036.
PMID: 38182098
Background: Hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency is characterized by unpredictable recurrent episodes of swelling affecting the skin and the mucosa tissues, including gastrointestinal tract and/or oropharyngeal-laryngeal mucosae....
10.
Cohn D, Aygoren-Pursun E, Bernstein J, Farkas H, Lumry W, Maurer M, et al.
Clin Transl Allergy
. 2023 Sep;
13(9):e12288.
PMID: 37746795
Background: Hereditary angioedema (HAE) with C1-inhibitor deficiency (HAE-C1-INH) is characterized by recurrent, debilitating episodes of swelling. Sebetralstat, an investigational oral plasma kallikrein inhibitor, demonstrated promising efficacy for on-demand treatment of...